Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial

Published:2017-09 Issue:9 Volume:18 Page:1211-1220
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Derks Marloes G M,Blok Erik J,Seynaeve Caroline,Nortier Johan W R,Kranenbarg Elma Meershoek-Klein,Liefers Gerrit-Jan,Putter Hein,Kroep Judith R,Rea Daniel,Hasenburg Annette,Markopoulos Christos,Paridaens Robert,Smeets Jan B E,Dirix Luc Y,van de Velde Cornelis J H

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Tamoxifen for early breast cancer: an overview of the randomised trials;Lancet,1998

2. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials;Lancet,2015

3. Residual risk of breast cancer recurrence 5 years after adjuvant therapy;Brewster;J Natl Cancer Inst,2008

4. Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important?;Pritchard;J Clin Oncol,2011

5. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial;van de Velde;Lancet,2011

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapy in Breast Cancer;American Society of Clinical Oncology Educational Book;2024-06-01

2. Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial;Clinical Cancer Research;2024-02-12

3. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan;Expert Opinion on Pharmacotherapy;2024-02-11

4. Systemic Therapy for Breast Cancer;Breast Cancer;2024

5. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022);Clinical and Translational Oncology;2023-06-16